Who
Ron Martell
President, CEO and Director
Company insider
Files Form 4 as: President, CEO and Director, Jasper Therapeutics; Director, Cerenome; Executive Chairman, Kalobios Pharmaceuticals; Chief Executive Officer, Eloxx Pharmaceuticals; President and CEO, NeurogesX; Chief Executive Officer, Poniard Pharmaceuticals; Former SVP, Commercial Ops, Imclone Systems.
In numbers
- Trades disclosed
- 69
- Buys
- 2
- Sells
- 3
- Bought
- $115K
- Sold
- $1.1M
- Companies
- 7
- Companies where not an officer
- 1
- First trade
- 18 Jan 2006
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —234,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —234,000 at $0.00 | filing |
| 22 Sep 2025filed 24 Sep 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —41,000 | filing |
| 22 Sep 2025filed 24 Sep 2025 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K41,000 at $2.43 | filing |
| 4 Jun 2025filed 6 Jun 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —234,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 10 Jun 2024filed 12 Jun 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Jun 2024filed 12 Jun 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 15 Feb 2024filed 20 Feb 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Oct 2023filed 13 Oct 2023 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code F | $74K87,531 at $0.85 | filing |
| 12 Apr 2023filed 14 Apr 2023 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code F | $128K87,531 at $1.46 | filing |
| 17 Mar 2023filed 20 Mar 2023 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 2 Feb 2023filed 3 Feb 2023 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,093,831 at $0.00 | filing |
| 12 Oct 2022filed 13 Oct 2022 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code A | —506,250 at $0.00 | filing |
| 21 Mar 2022filed 23 Mar 2022 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,704,328 at $0.00 | filing |
| 26 Jan 2017filed 27 Jan 2017 | CNSY Cerenomeoption or derivative · Medical Devices | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 28 Oct 2015filed 28 Oct 2015 | Kalobios Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —3,125 at $0.00 | filing |
| 28 Sep 2015filed 28 Sep 2015 | Kalobios Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —3,125 at $0.00 | filing |
| 28 Aug 2015filed 22 Sep 2015 | Kalobios Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —3,125 at $0.00 | filing |
| 30 Jul 2015filed 30 Jul 2015 | Kalobios Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —3,125 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.